---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-24-000168"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:56:45.576098+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M

## Summary
- Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.
- Total test reports 26,010 (+41% YoY); TissueCypher up 115%, IDgenetix up 81%, DecisionDx-SCC up 49%.
- Raises full-year 2024 revenue guidance to $320-330M from prior $275-300M.
- Cash, equivalents and marketable securities $279.8M at Sept 30, 2024.
- Q3 operating cash flow $23.3M vs $5.0M prior year.

## SEC filing metadata
- accession: 0001447362-24-000168
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000168/0001447362-24-000168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000168/cstl-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-24-000168
- JSON: https://secwatch.observer/filing/0001447362-24-000168.json
- Plain text: https://secwatch.observer/filing/0001447362-24-000168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.